TherapeuticsMD announces commercial availability of BIJUVA in the U.S.
TherapeuticsMD announced the commercial availability of BIJUVA in the United States. BIJUVA is an FDA-approved bio-identical hormone therapy combination of estradiol and progesterone in a single, oral daily capsule for the treatment of moderate-to-severe vasomotor symptoms due to menopause in women with a uterus. BIJUVA offers a balance of bio-identical estradiol to reduce moderate to severe hot flashes combined with bio-identical progesterone to reduce risks to the endometrium. As of April 19, 2019, three of the top ten commercial payers - Express Scripts, Anthem and Aetna - will be adjudicating BIJUVA in the commercial health insurance channel for the majority of their formulary designs. TherapeuticsMD plans to hold an Investor Day in New York on Monday, June 10, 2019 to highlight its commercial strategy for its product portfolio, including BIJUVA.